Osiris Therapeutics, Inc. (NASDAQ:OSIR)

CAPS Rating: 1 out of 5

A stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.

Recs

2
Player Avatar zzlangerhans (99.73) Submitted: 9/23/2011 11:21:06 AM : Outperform Start Price: $4.96 OSIR Score: +22.70

I scored on a couple of hold-my-nose green thumbs on Osiris last year so I thought I might give it a shot again as I drive for score leadership. Of course, the same strategy could put me in the cellar. Osiris continues to singlemindedly pursue a stem cell therapy that all available data indicates simply does not work. Right now there's a phase III trial of Prochymal in Crohn's that has already been terminated once for futility in an interim analysis, and phase II trials of Prochymal in acute MI and new onset diabetes with data expected in Q4 2011 or Q1 2012. A Prochymal submission to HealthCanada appears to be in regulatory limbo.

Now that I've completed the requisite disclaimer, I think it's more than likely that Osiris has a 10-15% rebound in them before more bad news hits. CAPS only, without a doubt.

Featured Broker Partners


Advertisement